Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 5, 2017, Pages 841-848

  Sundelin, E I O ^a   Gormsen, L C ^a   Jensen, J B ^a   Vendelbo, M H ^a   Jakobsen, S ^a   Munk, O L ^a   Christensen, M M H ^b   Brosen K ^b,c   Frokiaer J ^a   Jessen, N ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN C 11; ORGANIC CATION TRANSPORTER 1; TRACER; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; METFORMIN; OCTAMER TRANSCRIPTION FACTOR 1; POU2F1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE ABSORPTION; MALE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; WILD TYPE; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; LIVER; MALE; METFORMIN; MIDDLE AGED; OCTAMER TRANSCRIPTION FACTOR-1; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY;

EID: 85020066931     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.701     Document Type: Article

References (33)

1. Graham, G.G. et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81–98 (2011).
2. Bailey, C.J. & Turner, R.C. Metformin. N. Engl. J. Med. 334, 574–579 (1996).
3. Koepsell, H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol. Aspects Med. 34, 413–435 (2013).
4. Jensen, J.B. et al. [11C]-Labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency. Diabetes 65, 1724–1730 (2016).
5. Nies, A.T. et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50, 1227–1240 (2009).
6. Shu, Y. et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. USA 100, 5902–5907 (2003).
7. Kerb, R. et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12, 591–595 (2002).
8. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422–1431 (2007).
9. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273–280 (2008).
10. Christensen, M.M. et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet. Genomics 21, 837–850 (2011).
11. Tzvetkov, M.V. et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86, 299–306 (2009).
12. Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R., Palmer, C.N. & Pearson, E.R. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64, 1786–1793 (2015).
13. Shingaki, T. et al. Quantitative evaluation of mMate1 function based on minimally invasive measurement of tissue concentration using PET with [(11)C]metformin in mouse. Pharm. Res. 32, 2538–2547 (2015).
14. Hume, W.E. et al. The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Bioorg. Med. Chem. 21, 7584–7590 (2013).
15. Gormsen, L.C. et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J. Nucl. Med. 57, 1920–1926 (2016).
16. 11C-metformin: radiosynthesis and preclinical proof-of-concept studies. J. Nucl. Med. 57, 615–621 (2016).
17. Viollet, B. & Foretz, M. Revisiting the mechanisms of metformin action in the liver. Ann. Endocrinol. (Paris) 74, 123–129 (2013).
18. Christensen, M.M. et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet. Genomics 23, 526–534 (2013).
19. Seitz, T. et al. Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med. 7, 56 (2015).
20. Zhou, K. et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58, 1434–1439 (2009).
21. Dujic, T. et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a MetGen meta-analysis. Clin. Pharmacol. Ther. 2016 (epub ahead of print).
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
23. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. & Neil, H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
24. Higgins, J.W., Bedwell, D.W. & Zamek-Gliszczynski, M.J. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab. Dispos. 40, 1170–1177 (2012).
25. Wang, D.S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H. & Sugiyama, Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510–515 (2002).
26. Moses, W.W. Fundamental limits of spatial resolution in PET. Nucl. Instrum. Methods Phys. Res. A. 648 (suppl. 1), S236–S240 (2011).
27. Pentikäinen, P.J., Neuvonen, P.J. & Penttilä, A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16, 195–202 (1979).
28. Sum, C.F., Webster, J.M., Johnson, A.B., Catalano, C., Cooper, B.G. & Taylor, R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet. Med. 9, 61–65 (1992).
29. Koepsell, H., Lips, K. & Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227–1251 (2007).
30. Schaeffeler, E. et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3, 82 (2011).
31. Stepensky, D., Friedman, M., Raz, I. & Hoffman, A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab. Dispos. 30, 861–868 (2002).
32. Christensen, M.M. et al. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur. J. Clin. Pharmacol. 71, 691–697 (2015).
33. Pedersen, R.S., Christensen, M.M. & Brøsen, K. Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur. J. Clin. Pharmacol. 68, 1463–1464 (2012).